Navigation Links
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

ons (NDAs) and supplemental NDAs (sNDAs). He joins Sunesis from Reliant Pharmaceuticals, Inc., where he served as Senior Vice President, Research & Development and Medical Affairs. In this role, he was responsible for the strategic direction and day-to-day operations, as well as the organizational growth, of Reliant's clinical R&D and product development capabilities. Previously, Dr. Ketchum served as Senior Vice President, Operations and Regulatory Affairs for IntraBiotics Pharmaceuticals, Inc. from 2002 to 2005, where he was responsible for regulatory affairs, project management, quality assurance, and supply chain management in support of late-stage clinical research. Dr. Ketchum also held positions of increasing responsibility in regulatory affairs during his nearly eight-year tenure at ALZA Corporation from 1994 to 2002, most recently as Senior Director, Regulatory Affairs. He earned a Ph.D. in Pharmacology from University College London (funded by the Sandoz Institute for Medical Research) and a B.S. in Biological Sciences from Stanford University.

Over the past year, Dr. Bolton has served as a consultant to Sunesis on the development of voreloxin. As a medical oncologist, she brings more than a decade of industry experience in the clinical development of oncology therapeutics to her new post as Vice President, Clinical Development. From 2004 to 2005, Dr. Bolton was Vice President, Clinical Development for Sonus Pharmaceuticals, Inc. responsible for Phase 1-3 clinical development of the company's lead molecule. Before that, she served as Medical Director with ZymoGenetics, Inc. and as Medical Director for Cell Therapeutics, Inc., leading each company's clinical development programs and providing input on regulatory strategy. From 1999 to 2001, Dr. Bolton led the Herceptin(R) post-marketing team at Genentech, Inc., where she served as a Clinical Scientist. Prior to her industry experience, Dr. Bolton spent several years as a practicing oncologist, most r
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ... and forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Earlier this year in a June ... of the Adult Stem Cell Technology Center, LLC ( ... under appreciated unique property of adult tissue stem cells. ... Misunderstood in the Past, Important for the Future,” embodied ... He gave the address at the 4th World Congress ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Bio-Optronics, Inc. and flexcipio s.a. are pleased ... Bio-Optronics, Clinical Conductor Clinical Trial Management System (CTMS) ... This aligns the industry,s most comprehensive enterprise CTMS, ... with the best tools to optimize efficiency, productivity, ...
... European Trials Commencing for Injectable Biopolymer to Repair ... Symphony Medical, Inc., a developer of novel biopolymer ... patented flagship technology, Algisyl-LVR(R), was used on a ... 50-year-old male who was suffering from chronic heart ...
... BioVex Inc, a company developing next generation biologics for the ... that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 ... III and Stage IV melanoma had initiated. The study has ... United Kingdom, Germany and Australia due to open later in ...
Cached Biology Technology:Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity 2Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 2Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 3Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 4BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... a virus,s tiny exterior is a store of energy ... host cell, this pent-up energy is released, propelling the ... a virus factory. For the first time, Carnegie Mellon ... associated with the expulsion of viral DNA, a pivotal ...
... have found a critical piece in the evolutionary puzzle ... centuries ago. The team, from the School of ... developed into more complex cells and found this crucial ... previously thought. Team leader and ARC Federation ...
... A new study of children in Ukraine has found ... quality of care and the relationship between children and ... Based on their findings, the researchers highlight the importance ... relationships by changing caregivers, working schedules and providing training ...
Cached Biology News:Carnegie Mellon first to measure energy released from a virus during infection 2Carnegie Mellon first to measure energy released from a virus during infection 3An answer to another of life's big questions 2For HIV-infected children, quality of caregiver relationship is crucial 2